Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.81B 2.42B 2.28B 2.07B 3.89B 268B 3.96B 26.68B 10.43B 134B 10.53B 10.31B 446B P/E 2026 *
-241x
P/E 2027 * 39.4x
Enterprise Value 2.81B 2.42B 2.28B 2.07B 3.89B 268B 3.96B 26.68B 10.43B 134B 10.53B 10.31B 446B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.05x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day+2.57%
1 week+1.51%
Current month+8.36%
1 month+1.32%
3 months-2.16%
6 months-4.88%
Current year-2.70%
1 week 46.26
Extreme 46.26
48.6
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 41.78
Extreme 41.783
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Free

Chief Financial Officer

1,250 0.0022%
29/07/26 Free

Founder

29,849 0.0532%
29/07/26 Free

Chief Technology Officer

750 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%+1.51%+13.28%+51.88% 2.81B
+0.21%+5.65%+61.31%+25.01% 335B
-2.29%-5.12%+21.64%-15.21% 68.61B
-2.00%-4.33%+46.66%+124.13% 11.2B
-1.26%+1.30%-2.03%-4.67% 8.49B
-0.34%+2.22%-13.22%-8.59% 4.84B
+1.45%+3.85%-26.84%+16.87% 4.42B
+0.32%-2.16%+0.82%+45.93% 4.28B
-1.59%-2.84%-4.94%-3.92% 2.19B
-1.03%+3.73%-28.21%+31.00% 2.03B
Average -0.40%+0.14%+6.85%+26.24% 44.4B
Weighted average by Cap. -0.25%+3.44%+50.29%+20.54%

Financials

2026 *2027 *
Net sales 886M 765M 719M 654M 1.23B 84.7B 1.25B 8.42B 3.29B 42.42B 3.33B 3.25B 141B 1.37B 1.18B 1.11B 1.01B 1.9B 131B 1.93B 13.04B 5.1B 65.68B 5.15B 5.04B 218B
Net income -11.54M -9.97M -9.37M -8.52M -16.02M -1.1B -16.28M -110M -42.92M -553M -43.34M -42.4M -1.84B 71.54M 61.79M 58.06M 52.81M 99.28M 6.84B 101M 680M 266M 3.43B 269M 263M 11.38B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
14/08/26 US$48.27 +2.38% 331,731
13/08/26 US$47.15 -1.50% 667,871
12/08/26 US$47.87 +2.11% 667,316
11/08/26 US$46.88 -0.40% 669,685
10/08/26 US$47.07 -1.20% 762,174
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
48.27USD
Average target price
61.75USD
Spread / Average Target
+27.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock